Kyntra Bio, Inc.
KYNBHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Kyntra Bio, Inc. focuses on Biotechnology services and products. Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The $34.6M market capitalization puts KYNB squarely in micro-cap range for its industry. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Market Cap
$34.6M
Beta
1.06
P/E (TTM)
—
P/E (Fwd)
-0.60
EPS (TTM)
$-7.64
EPS (Fwd)
$-14.23
ROE
—
ROA
-22.5%
Cash
$91.3M
Total Debt
$0
Free CF
$54.1M
52W Change
-25.5%
Annual Financials
Cash vs Debt
Where KYNB stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, KYNB finished 18.47% above its 150-day moving average ($7.20) and 12.38% above its 200-day moving average ($7.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KYNB overbought or oversold?
At the September 3, 2026 close, KYNB's RSI(14) was 78.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Kyntra Bio, Inc. reports $91.3M in cash and $0 in total debt. Annual free cash flow of $54.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Revenue has pulled back from $140.7M (2022) to $6.4M (2025), a 95% decline worth watching.
As with any equity investment, KYNB carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kyntra Bio, Inc.'s trajectory.